drugset / Trial / NCT04850937

Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer

NCT04850937

Completed 90 enrolled Yangzhou University
RandomizedParallel-groupDouble-blindPrevention

Summary

esketamine is an optical isomer of ketamine. Compared with ketamine, esketamine has the characteristics of higher effective value, stronger receptor affinity, less adverse reactions of nervous system, and pharmacokinetics is controllable. Domestic and foreign studies have focused on the therapeutic effect of esketamine on major depression, but less attention has been paid to perioperative depression.This study intends to explore the effect of small doses of esketamine on patients with breast cancer.Postoperative depression and pain are observed.

Timeline

Start
2021-02-10
Primary completion
2021-04-10
Completion
2022-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 0.25 mg/kg Intravenous

Indications